13F Holdings
中文EN

MLTX MoonLake Immunotherapeutics

Pharmaceutical Preparations · Nasdaq · SEC CIK 1821586 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-29.9%
TTM EPS YoY-9.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-81.6%
ROA-57.3%
ROIC (approx.)-384.1%
Asset turnover—

Leverage & solvency

Liabilities / assets29.4%
Debt / equity0.26x
Current ratio9.13x
Interest coverage-28.98x

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$202.86M$112.77M$31.80M$42.05M—
SG&A expense$41.97M$30.32M$22.32M$23.01M$4.57M
Operating income-$244.83M-$143.09M-$54.12M-$65.06M-$4.57M
Interest expense$7.25M$0$0——
Pretax income-$229.71M-$120.96M-$43.98M-$64.47M—
Income tax$611,000$282,000$94,000$36,366—
Net income-$227.32M-$118.94M-$36.01M-$49.97M-$4.54M
EBITDA-$242.22M-$141.71M-$53.75M-$64.90M—
EPS (basic)-3.53-1.89-0.73-1.70-0.31
EPS (diluted)-3.53-1.89-0.73-1.70-0.31
Weighted avg. shares (diluted)64.46M62.87M49.12M29.36M360.00M
Balance sheet
Cash & equivalents$334.52M$180.43M$451.17M$39.51M$8.04M
Short-term investments$59.45M$267.60M$59.84M$32.61M$0
Current assets$421.69M$474.29M$514.17M$76.51M$9.64M
PP&E, net$577,000$722,000$320,865$49,389$45,739
Total assets$424.43M$477.93M$526.54M$76.84M$9.68M
Current liabilities$45.48M$22.46M$9.97M$7.67M$21.09M
Short-term debt———$0$15.00M
Long-term debt$74.10M$0———
Total debt$74.10M$0———
Total liabilities$119.95M$24.54M$13.05M$8.08M$21.33M
Shareholders' equity$304.48M$446.82M$495.68M$48.90M-$11.65M
Net debt-$260.42M-$180.43M———
Cash flow statement
Operating cash flow-$196.01M-$116.59M-$42.78M-$55.89M-$611,071
Capital expenditure$35,000$520,000$284,000$16,009—
Free cash flow-$196.04M-$117.11M-$43.06M-$55.91M—
Investing cash flow$202.99M-$205.60M-$25.18M-$32.34M—
Financing cash flow$146.00M$51.31M$479.70M$119.69M-$58,063
Depreciation & amortization$2.62M$1.39M$370,000$164,783—
Stock-based compensation$12.90M$7.28M$7.11M$9.65M—
Share buybacks—$50$0$0—

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.